Replies to post #1162 on BioCurex, Inc.(fka BOCX)

[good-pal]

"Let's say for the sake of argument that the results of the blind test were as earthshatteringly impressive as Biocurex implies"

i believe that the blind test results were GOOD but not as good as the company want us to believe and remember that the SEC investigating bocx for DATA accuracy claims and few other things.

"This scenario is very plausible in my eyes"

but not in my eyes

"That being the case, your theory about Abbott having the upperhand is utter foolishness. The fact that we are small and on the pinks is irrelavent, if the technology is on the money"

the foolishness is to believe that a that a PINK SHEET( under investigation by the sec) company with 35 mill market cap have the upper hand against a 66 BIL mammoth company like AABOTT.
and dont forget that they did not even Allowed bocx to use ABBOTT name without their written consent.

"Most of the longtermers are convince that the technology is everything it's hyped up to be."

most of them but not all of them. Im long and i believe SOME of the hype but all of it.

"You obviously question it, but part of you believes it cause you bought some. You probably won't sell till you know definitively whether it works."

again...im long on bocx, and i believe in recaf tech and it will make money for our company and for us but i DO NOT believe its "The holy grail of cancer diagnosis."
and i do not believe the 90+ recaf accuracy in detecting cancer (i hate to say it but even the SEC is on my side in questioning THE 90+ accuracy claims)

[good-pal]

15 mil in upfront for early detection of colorectal cancer!!!

EXACT Sciences Corporation (Nasdaq: EXAS - News) and Laboratory Corporation of America® Holdings (NYSE: LH - News; LabCorp®) today announced the creation of an exclusive, long-term strategic partnership to commercialize PreGen-Plus(TM), EXACT Sciences' proprietary, non-invasive technology for the early detection of colorectal cancer in the average-risk population. As part of the agreement, in addition to certain royalty fees, LabCorp could pay EXACT Sciences as much as $75 million in upfront, milestone and performance-based payments for a five-year exclusive license, followed by a non-exclusive license for the life of the patents. The introduction of PreGen-Plus, expected in the first half of 2003, will mark the broadest commercial application of discoveries made about the human genome to address a major healthcare problem such as colorectal cancer -- the most deadly cancer among non-smokers in the United States. There is no other DNA-based test currently available for the early detection of cancer in an average-risk population.

It is estimated that this year approximately 150,000 Americans will be diagnosed with colorectal cancer and approximately 57,000 Americans will die from the disease. The American Cancer Society recommends that the 80 million Americans who are over the age of 50 be screened regularly for colorectal cancer, which, if detected at an early stage, has a cure rate of more than 90 percent. A majority of people, however, avoid screening because of the inconvenience and discomfort associated with certain currently available screening methods, with the result that most colorectal cancer cases are detected at a later stage when the cure rate is less than 50 percent.

LabCorp's first payment to EXACT Sciences of $15 million was made upon the signing of the agreement, and the second payment of $15 million will be made upon the commercial launch of PreGen-Plus, which is expected in the first half of 2003. Of the remaining $45 million, milestone payments from LabCorp totaling $30 million will be based upon EXACT Sciences deliverables related to scientific acceptance, reimbursement approval and technology improvements and $15 million will be based upon the achievement of significant revenue thresholds. In addition to these payments, EXACT Sciences will receive a royalty fee for each PreGen-Plus test performed by LabCorp. In conjunction with the partnership, EXACT Sciences has issued to LabCorp a warrant to purchase 1,000,000 shares of EXACT Sciences common stock, exercisable over the next three years at an exercise price of $16.09.

"The proprietary technology underlying the PreGen-Plus assay creates a very accurate and patient-friendly test, and therefore represents a significant step forward in the early detection of colorectal cancer in the average-risk population," said Thomas P. Mac Mahon, LabCorp's Chairman and CEO. "We believe PreGen-Plus could be the most important molecular test identified to date for the millions of Americans who are candidates for colorectal cancer screening annually."

Mr. Mac Mahon continued, "Our agreement with EXACT Sciences is another example of LabCorp's pioneering leadership position in molecular diagnostics and our ability to recognize the potential of DNA-based testing. EXACT Sciences brings that same visionary approach in applying the discoveries of the human genome to create novel DNA-based assays that address major healthcare problems. We are excited about combining our skills with EXACT Sciences' to improve diagnostic testing for cancer."

"As the first DNA-based test that will be used for population-based cancer screening, PreGen-Plus truly changes the molecular diagnostics landscape," said Don Hardison, EXACT Sciences' President and CEO. "The scope of this partnership -- both in economic terms and, more importantly, in terms of lives saved -- highlights the power of applied genomics. As a leader in bringing the knowledge of the human genome to reality, EXACT Sciences is delighted to be working with LabCorp, given its unique scale, expertise and infrastructure, to make this important test widely available. We are confident that the fruits of our strategic relationship will result in greater numbers of Americans being screened for the disease and the prevention of many deaths from colorectal cancer."

PreGen-Plus works by isolating human DNA that is shed in the colon everyday and carried out of the body in stool, and analyzing that DNA for mutations associated with colorectal cancer. PreGen-Plus is a completely non- invasive, patient-friendly technology that requires no dietary modification or bowel preparation. The simple process involves collecting a single stool sample in the privacy of a patient's own home, and shipping the sample in a supplied container and packaging materials to LabCorp's facilities for analysis. Following the analysis, LabCorp will send the test results to the patient's physician for use in connection with future monitoring and treatment.
http://www.flagshipventures.com/news/06272002p.html